Mark Middleton is Professor of Experimental Cancer Medicine in the Department of Oncology, consultant Medical Oncologist at the Oxford Cancer and Haematology Centre and Head of the Department of Oncology at the University of Oxford.

Mark was the Lead Cancer Clinician for the Oxford University Hospitals NHS Foundation Trust (2012 -2017) directed the Early Phase Cancer Trials Unit. He is Director of the Cancer Research UK Oxford Centre and co-leader of the Cancer Theme in the NIHR Biomedical Research Centre.

He studied medicine at Cambridge and Oxford and trained in medical oncology at the Christie Hospital. Mark has overseen the development of internationally leading melanoma and upper GI clinical research groups and establishment of portfolios of early phase radiotherapy and haematooncology trials in Oxford. He is involved in the evaluation of novel immunotherapeutics, including pre-clinical development, trial design, proof of mechanism and proof of concept.

In his role as Cancer Centre director, Mark has established a new Doctoral Training Programme, for a DPhil in Cancer Science, offering non-clinical, medical student and clinical fellowships and programmes for post-doctoral research.

GROUP MEMBERS

Shivan Sivakumar, Academic Clinical Lecturer

Victoria Woodcock, Clinical Research Fellow

Recent publications

Tebentafusp, a TCR/anti-CD3 bispecific fusion protein targeting gp100, potently activated anti-tumor immune responses in patients with metastatic melanoma.
Journal article

Middleton MR. et al, (2020), Clin Cancer Res
Intratumoural immunotherapies for unresectable and metastatic melanoma: current status and future perspectives.
Journal article

Middleton MR. et al, (2020), Br J Cancer
Immune responses in pancreatic cancer may be restricted by prevalence of activated regulatory T-cells, dysfunctional CD8+ T-cells, and senescent T-cells
Journal article

Sivakumar S. et al, (2020)
ctDNA monitoring using patient-specific sequencing and integration of variant reads.
Journal article

Wan JCM. et al, (2020), Sci Transl Med, 12
Tuning Transcription Factor Availability through Acetylation-Mediated Genomic Redistribution.
Journal article

Louphrasitthiphol P. et al, (2020), Mol Cell

More publications